Literature DB >> 10885361

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

B Modell, M Khan, M Darlison.   

Abstract

About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10885361     DOI： 10.1016/S0140-6736(00)02357-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  119 in total

1.  Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry.

Authors:  B Modell; R Harris; B Lane; M Khan; M Darlison; M Petrou; J Old; M Layton; L Varnavides
Journal:  BMJ       Date:  2000-02-05

2.  Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Authors:  Janet L Kwiatkowski; Hae-Young Kim; Alexis A Thompson; Charles T Quinn; Brigitta U Mueller; Isaac Odame; Patricia J Giardina; Elliott P Vichinsky; Jeanne M Boudreaux; Alan R Cohen; John B Porter; Thomas Coates; Nancy F Olivieri; Ellis J Neufeld
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

Review 3.  Cardiovascular magnetic resonance and the evaluation of heart failure.

Authors:  James C C Moon; Sanjay K Prasad
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

4.  The thalassemias and related disorders.

Authors:  Alain J Marengo-Rowe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-01

5.  Diagnosis and management of transfusion iron overload: the role of imaging.

Authors:  John C Wood
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

6.  Providers' Perspectives on Treating Patients With Thalassemia.

Authors:  Taylor Radke; Susan Paulukonis; Mary M Hulihan; Lisa Feuchtbaum
Journal:  J Pediatr Hematol Oncol       Date:  2019-10       Impact factor: 1.289

7.  Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.

Authors:  Guanheng Yang; Wansheng Shi; Xingyin Hu; Jingzhi Zhang; Zhijuan Gong; Xinbing Guo; Zhaorui Ren; Fanyi Zeng
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 8.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

9.  Complications and treatment of patients with β-thalassemia in France: results of the National Registry.

Authors:  Isabelle Thuret; Corinne Pondarré; Anderson Loundou; Dominique Steschenko; Robert Girot; Dora Bachir; Christian Rose; Vincent Barlogis; Jean Donadieu; Mariane de Montalembert; Isabelle Hagege; Brigitte Pegourie; Claire Berger; Marguerite Micheau; Françoise Bernaudin; Thierry Leblanc; Laurence Lutz; Frédéric Galactéros; Marie-Claude Siméoni; Catherine Badens
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

10.  Rapid Screening for Deleted Form of β-thalassemia by Real-Time Quantitative PCR.

Authors:  Liang-Yin Ke; Jan-Gowth Chang; Chao-Sung Chang; Li-Ling Hsieh; Ta-Chih Liu
Journal:  J Clin Lab Anal       Date:  2016-08-16       Impact factor: 2.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.